Drugs / HB0017
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05442788 | Sep 2021 → May 2022 | psoriasis | Huabo Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04505033 | Oct 2020 → Jan 2021 | — | Huabo Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06592274 | Sep 2024 → Apr 2025 overdue | psoriasis | Huabo Biopharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05531682 | Oct 2022 → May 2023 | psoriasis | Huabo Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06477237 | Mar → Aug 2024 | psoriasis | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505033 ↗ |
| Modality | Monoclonal antibody | “HB0017, a humanized monoclonal antibody that targets IL-17A” PMID 37669307 ↗ Dec 2023 |
| Route | Subcutaneous | “HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings.” NCT04505033 ↗ |
| Target | IL17A | “HB0017, a humanized monoclonal antibody that targets IL-17A” PMID 37669307 ↗ Dec 2023 |